Sumitomo Pharma Co., Ltd. (DNPUF)

OTCMKTS · Delayed Price · Currency is USD
13.08
+0.04 (0.35%)
At close: Mar 26, 2026
Market Cap5.37B +184.8%
Revenue (ttm)2.89B +21.6%
Net Income702.17M
EPS1.77
Shares Outn/a
PE Ratio7.65
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume150
Average Volume1,917
Open13.08
Previous Close13.03
Day's Range13.08 - 13.08
52-Week Range4.00 - 19.20
Beta0.54
RSI50.61
Earnings DateMay 13, 2026

About Sumitomo Pharma

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson’s disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has coll... [Read more]

Sector Healthcare
Founded 1897
Employees 3,832
Stock Exchange OTCMKTS
Ticker Symbol DNPUF

Financial Performance

Financial numbers in JPY Financial Statements

News

Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript

Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript

5 weeks ago - Seeking Alpha

Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment

Shares of Japan's Sumitomo Pharma fell over 12%. Japanese government endorsed the company's iPS cell-based therapy for Parkinson's and heart disease.

5 weeks ago - CNBC